Closed Pfizer biopharma facility in Everett gets a new owner and a mystery tenant

A bio-manufacturing facility in Everett, Wash., which was built by Seattle biotech giant Seagen but never opened under its Pfizer ownership, is getting a new lease on life.

Breakthrough Properties, a life sciences real estate company, said Friday that it has acquired the 270,000-square-foot facility at 215 Shuksan Way for $78 million and leased the entire campus for 21 years to an unnamed global biopharmaceutical company.

Seagen invested approximately $350 million to build out the facility, which was designed for drug manufacturing, quality-control labs, warehousing and distribution. But the company never moved in after drug maker Pfizer acquired Seagen for $43 billion in 2023.

“Pfizer regularly evaluates our manufacturing network to ensure capacity is effectively utilized based on projected product demands,” the company said in a statement to GeekWire in 2024. “After careful evaluation, we have made the difficult decision to wind down construction of the site.”

The facility sits about 25 miles north of Seattle along the I-5 corridor and is Breakthrough Properties’ first investment in the Puget Sound region.

The deal comes as pharmaceutical companies increase investment in U.S. manufacturing capacity. Breakthrough said major drugmakers have announced more than $600 billion in recent commitments to expand domestic production and strengthen supply chains.

The Everett facility was part of Seagen’s broader manufacturing expansion before the company was acquired by Pfizer for $43 billion. GeekWire previously reported on Seagen’s plans for the 270,000-square-foot Everett facility.

Breakthrough Properties is a joint venture between global real estate company Tishman Speyer and biotech investment firm Bellco Capital. A spokesperson for the company, which owns and develops life sciences properties in the U.S. and Europe, declined to provide details on the new tenant or the move-in date.